Solid Biosciences公司SGT-003在40名参与者中总体耐受性良好,安全性特征令人鼓舞

美股速递
Mar 12

Solid Biosciences公司宣布,其候选疗法SGT-003在一项涉及40名参与者的研究中展现出良好的耐受性。初步数据显示,该疗法的安全性特征积极,为后续临床开发提供了支持。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10